Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04036136 · ClinicalTrials.gov registry record · NA
Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 116
- Enrollment target
NCT04036136 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 116 participants.
The verdict
NCT04036136, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 116 participants
- Enrollment target
Study Summary
The overall goal of this project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA), using ultra-high field functional neuroimaging. There is a critical need for a validated treatment that specifically targets anhedonia, and this project will evaluate the effects of this new treatment on anhedonia and will establish how this treatment impacts brain systems that mediate reward processing, clinical symptoms of anhedonia, functional outcomes, and behavioral indices of reward processing. This work will also identify brain targets by which future novel anhedonia treatment may be evaluated.
Interventions
- BEHAVIORAL Behavioral Activation
- BEHAVIORAL Mindfulness Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2023-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04036136
The ClinicalTrials.gov registry entry for NCT04036136 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Behavioral Activation is the first listed.
NCT04036136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04036136 about?
NCT04036136 is a clinical study titled "Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase". The overall goal of this project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA), using ultra-high field functional neuroimaging. There is a critical need for a validated treatment that specifically targets anhedonia, and thi...
What is the current status of trial NCT04036136?
This trial is currently completed. It is a NA study. The enrollment target is 116 participants. The study started on 2019-08-01. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT04036136?
The interventions under investigation include: Behavioral Activation (BEHAVIORAL), Mindfulness Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT04036136?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.